| Literature DB >> 31108564 |
Marijke Nynke Boersma1, Corlina Johanna Alida Huibers1, Anna Clara Drenth-van Maanen1, Mariëlle Henriëtte Emmelot-Vonk1, Ingeborg Wilting2, Wilma Knol1.
Abstract
AIMS: The Systematic Tool to Reduce Inappropriate Prescribing is a method to assess patient's medication and has been incorporated into a clinical decision support system: STRIP Assistant. Our aim was to evaluate the effect of recommendations generated using STRIP Assistant on appropriate prescribing and mortality in a preoperative setting.Entities:
Keywords: clinical pharmacology; clinical pharmacology, clinical trials; elderly; geriatrics, drug safety; geriatrics, geriatric medicine; prescribing
Mesh:
Year: 2019 PMID: 31108564 PMCID: PMC6710520 DOI: 10.1111/bcp.13987
Source DB: PubMed Journal: Br J Clin Pharmacol ISSN: 0306-5251 Impact factor: 4.335
Consensus‐bases instructions to standardize the prescribing recommendations
| STOPP/START criteria | Confusion leading to discrepancies | Instructions how to use STOPP/START criteria and guidelines panel |
|---|---|---|
| PPO: | ||
| 1.START, A6/7 | ACE inhibitor and β‐blocker in all patients with coronary disease or only in patients who experienced cardiac ischaemia? | Beta‐blocker in patients with a history of coronary bypass or coronary stent (myocardial infarction not prerequisite) and ACE inhibitor (only) in patients with history of acute myocardial infarction. |
| 2. | The number of available blood pressure measurements was often limited. Should advice be given on the basis of fewer than 3 measurements? | Antihypertensive medication in patients in whom the target blood pressure was not achieved, regardless of the number of blood pressure measurements. |
| 3.START, E5 | Do all older patients need to use vitamin D supplement? | Vitamin D supplement in patients with known osteoporosis or other musculoskeletal disease (e.g. rheumatoid arthritis, intermittent claudication) and insufficient sunlight exposure. |
| 4.START, E3 | Do all older patients need to use calcium supplement? | Calcium supplement in patients with osteoporosis in combination with low dairy intake. |
| PIM: | ||
| 5.STOPP, A1 | Antidepressant use without a documented depression or anxiety disorder in medical history. Possibly the available medical history is not complete. | Antidepressant without documented depression in medical history. |
| 6.STOPP, A1 | Analgesic use without documentation of pain or disease that causes pain. Possibly the available medical history is not complete. | Analgesic without documentation of pain or disease that causes pain (e.g. osteoporosis, rheumatoid disease, (metastatic) cancer, surgery within 2 weeks) in medical history. |
| Dose adjustment: | ||
| 7. | Should the maximum dose for acetaminophen be 3 times daily or 4 times daily? | Acetaminophen >1 g 3 times daily adjust to a maximum 1 g 3 times daily in patients with chronic use. |
| 8. START A5 | Which dose should be advised for statins? | Simvastatin adjusted to 40 mg once daily, atorvastatin adjusted to dose 20 or 40 mg once daily. |
| 9. STOPP, F2 | Which dose should be advised for proton‐pump inhibitors? | Proton‐pump inhibitor pantoprazole or omeprazole as prophylaxis adjusted to 20 mg once daily. |
| Change in medication: | ||
| 10. START A7 | Should the following medication be changed? | Change drug when the patient is not using the first‐choice drug according to guidelines, for example: |
| 10A. | Metoprolol instead of propranolol in a patient with a history of myocardial infarction. | |
| 10B. | Metoprolol instead of sotalol or digoxin in a patient with a history of permanent atrial fibrillation. | |
| 10C. | Thiazide diuretic instead of diltiazem in a patient with a history of hypertension. | |
| Other considerations: | ||
| 11. | Is angiotensin inhibitor an alternative when there is an indication for an ACE inhibitor? | Angiotensin inhibitor is considered equivalent to ACE inhibitor. |
ACE = angiotensin‐converting‐enzyme; PIM = potentially inappropriate medication; PPO = potential prescribing omission; START = screening tool to alert doctors to right treatment; STOPP = screening tool of older person's prescriptions.
Figure 1Participant flow and cluster size
Baseline characteristics
| Characteristics | Intervention group ( | Control group ( |
| |
|---|---|---|---|---|
| Sex, | 34 (53.8) | 30 (5.8) | .94 | |
| Age (years) | 77.8 ± 5.7 | 79.0 ± 6.0 | .29 | |
| Renal function | 69.0 (52.0–84.0) | 69.5 (52.0–85.0) | .92 | |
| Smoking, | 10 (16.1) | 6 (1.2) | .43 | |
| Alcohol consumption, | 10 (16.1) | 8 (13.5) | .72 | |
| Total number of medications used per patient | 9 (6–12) | 9 (7–12) | .86 | |
| Number of PPOs per patient | 1 (0–2) | 1 (0–2) | .08 | |
| Number of PIMs per patient | 3 (1–5) | 2 (.5–3.5) | .87 | |
| Specialty operation, | .13 | |||
| General surgery | 3 (4.6) | 9 (15.3) | ||
| Cardiology | 12 (18.5) | 13 (22.0) | ||
| Oncological surgery | 23 (35.4) | 14 (23.7) | ||
| Orthopedic surgery | 15 (23.0) | 13 (22.0) | ||
| Urology | 5 (7.7) | 1 (1.7) | ||
| Vascular surgery | 7 (1.8) | 7 (11.7) | ||
| Other | 0 (0) | 2 (3.4) | ||
| CCI | 3 (0–9) | 3 (0–10) | .74 | |
| MMSE <24, | 5 (8.2) | 4 (6.8) | .81 | |
| Katz‐ADL ≥ 7, | 9 (14.1) | 3(5.5) | .06 | |
| Specialty and year of residency of the resident who treated the patient, | <.001 | |||
| Geriatric medicine | 2nd | 0 | 1 (1.7) | |
| 3rd | 9 (13.6) | 3 (5.1) | ||
| 4th | 4 (6.1) | 4 (6.8) | ||
| 5th | 17 (26.2) | 13 (22.0) | ||
| 6th | 0 | 17 (27.1) | ||
| Internal medicine | 1st | 0 | 1 (1.7) | |
| General practice medicine | 2nd | 10 (16.7) | 10 (16.9) | |
| Elderly care medicine | 2nd | 25 (38.5) | 10 (16.9) | |
PPOs = potential prescribing omissions based on screening tool of older person's prescriptions/screening tool to alert doctors to right treatment (STOPP/START) criteria version 2; PIMs = potentially inappropriate medications based on STOPP/START criteria version 2; CCI = Charlson comorbidity index; Katz‐ADL = 15 point Katz Index of Independence in Activities of Daily Living; MMSE = mini‐mental state examination. Missing n: renal function 7, smoking 5, alcohol consumption 5, CCI 4, MMSE 6, 15 Katz‐ADL index 5.
mean ± standard deviation.
median (interquartile range).
renal function measured as eGFR in ml/min/1,73m2.
P value based on χ2‐test.
P value based on Fisher exact test (2‐sided).
P value based on independent Student t test.
P value based on Mann–Whitney U test.
Number of resident‐implemented medication changes because of potential prescribing omission (PPO), potentially inappropriate medication (PIM) and suboptimal dosages made per patient by the resident in accordance with prescribing recommendations. Mortality in the intervention group vs control group
| Intervention group ( | Control group ( |
| |
|---|---|---|---|
| Number of PPO changes per patient (%) | 48 (73.8) | 57 (96.6) |
<.001 |
| 0 | 11 (16.9) | 2 (3.4) | |
| 1 | 6 (9.2) | 0 | |
| 2 | |||
| Number of PIM changes per patient (%) | 35 (53.8) | 50 (84.7) |
<.001 |
| 0 | 14 (21.5) | 8 (13.6) | |
| 1 | 8 (12.3) | 0 | |
| 2 | 8 (12.3) | 1 (1.7) | |
| ≥ 3 | |||
| Number of suboptimal dosage changes per patient (%) | |||
| 0 | 62 (95.4) | 59 (100) | .096 |
| 1 | 3 (4.6) | 0 | |
| Mortality, | 8 (13.1) | 7 (12.1) | .859 |
P value based on Mann–Whitney U.
P value based on generalized estimating equation analysis of association between intervention and number of patients with 0 or ≥ 1 PPOs/PIMs. Adjusted for the number of recommended PPO/PIM medication changes.
P value based on generalized estimating equation analysis of association between intervention and 3‐month postoperative mortality (death of all causes). Adjusted for age, sex and Charlson comorbidity index at screening. Missing n = 5.
Figure 2Average number of prescribing recommendations per patient, average number of medication changes in accordance with prescribing recommendations, and average number of additional changes by the resident per patient, because of potential prescribing omissions (PPOs); (A), potentially inappropriate medications (PIMs); (B), and suboptimal dosages (C) in the control and intervention groups. *P < .001. P values calculated using Mann–Whitney U
Number of potential prescribing omissions (PPOs) and potentially inappropriate medications (PIMs) before and after intervention/usual care identified with screening tool of older person's prescriptions/screening tool to alert doctors to right treatment criteria version 2
|
|
|
|
|---|---|---|
| Numbers of patients (%) with PPOs | ||
| 0 | 30 (46.2) | 36 (55.4) |
| 1 | 19 (29.2) | 17 (26.2) |
| 2 | 14 (21.5) | 10 (15.4) |
| ≥ 3 | 2 (3.0) | 2 (3.0) |
| Numbers of patients (%) with PIMs | ||
| 0 | 8 (12.3) | 12 (18.5) |
| 1 | 12 (18.5) | 16 (24.6) |
| 2 | 10 (15.4) | 11 (16.9) |
| ≥ 3 | 35 (53.8) | 26 (40.0) |
P values were based on generalized estimating equation regression model analysis of association between intervention and number of patients with 0 or ≥ 1 PPO/PIM, adjusted by the number of PPOs/PIMs at baseline. PPOs P = .36. PIMs P < .001.